Can I Take Reishi Mushroom with Praluent (Alirocumab)?

How Alirocumab Works and Why Supplement Interactions Matter

Alirocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing PCSK9 from degrading LDL receptors on hepatocytes. The result is a dramatic increase in LDL receptor recycling and, with it, LDL-C clearance from the bloodstream. In the ODYSSEY OUTCOMES trial (N=18,924), alirocumab 75 to 150 mg every two weeks reduced major adverse cardiovascular events by 15% compared with placebo over a median 2.8 years of follow-up [1].

Why Monoclonal Antibodies Differ from Small Molecules

Because alirocumab is a large protein degraded by proteolysis rather than cytochrome P450 enzymes, traditional drug-drug interaction screens (CYP inhibition, P-glycoprotein transport) do not apply [2]. That distinction matters. It means the interaction risk with reishi is not about competing for the same liver enzyme. Instead, the relevant question is whether reishi's pharmacodynamic effects (antiplatelet activity, immune modulation, or lipid-lowering overlap) create additive risk or benefit.

The Gap in Published Data

No randomized controlled trial, case series, or pharmacovigilance signal in the FDA Adverse Event Reporting System (FAERS) links reishi mushroom to adverse outcomes in patients taking any PCSK9 inhibitor. The absence of data does not equal safety. It means clinicians must reason from each agent's known pharmacology.

Reishi Mushroom Pharmacology: What Clinicians Should Know

Reishi (Ganoderma lucidum) contains over 400 bioactive compounds. The two classes most relevant to an alirocumab interaction assessment are triterpenoids (ganoderic acids) and polysaccharides (beta-glucans).

Antiplatelet and Anticoagulant Properties

Ganoderic acids inhibit platelet aggregation by interfering with thromboxane A2 synthesis. A 2016 in vitro study published in Phytochemistry demonstrated that ganoderic acid S suppressed ADP-induced platelet aggregation by 36% at 100 micromol/L [3]. A separate open-label pilot (N=10) found that 1.5 g/day of reishi extract for 4 weeks prolonged bleeding time by a mean of 1.2 minutes from baseline [4]. These effects are modest in healthy volunteers, but they become clinically meaningful when patients are already on anticoagulants or antiplatelets, a common co-prescription in the ASCVD population that receives alirocumab.

Immune Modulation and Beta-Glucans

Reishi beta-glucans stimulate macrophage phagocytosis and shift cytokine production toward a Th1-dominant profile (increased IL-2, IFN-gamma; decreased IL-4, IL-10) [5]. Alirocumab injection-site reactions occur in approximately 7% of patients [2]. Whether immune-priming supplements like reishi raise or lower that rate is unknown. The theoretical concern is that an upregulated innate immune system could amplify local injection-site inflammation, though no published case report supports this.

Lipid-Lowering Overlap

A 2015 Cochrane-registered systematic review of five RCTs (total N=398) found that Ganoderma lucidum preparations reduced total cholesterol by a mean of 11.4 mg/dL but did not reach statistical significance for LDL-C reduction (weighted mean difference: −7.2 mg/dL, 95% CI: −16.0 to 1.6) [6]. This effect is small relative to alirocumab's 50 to 60% LDL-C reduction, so additive hypocholesterolemia is not a practical concern.

Evaluating the Interaction: Pharmacokinetic vs. Pharmacodynamic

The distinction between these two categories determines whether dose separation, dose adjustment, or avoidance is warranted.

No Pharmacokinetic Conflict

Alirocumab is catabolized through target-mediated drug disposition (binding to PCSK9) and non-specific IgG clearance via the neonatal Fc receptor (FcRn) pathway [2]. It does not undergo hepatic CYP metabolism. Reishi triterpenoids do inhibit CYP3A4 and CYP2E1 in vitro [7], but these enzymes are irrelevant to alirocumab clearance. Dose-separation timing (take reishi two hours before or after Praluent) has no pharmacokinetic basis and is unnecessary for this specific pair.

Pharmacodynamic Overlap Is the Real Concern

The clinically relevant layer is pharmacodynamic. Three effects warrant monitoring:

1. Additive bleeding tendency. Patients on alirocumab often co-take aspirin, clopidogrel, or warfarin for secondary ASCVD prevention. Reishi adds a fourth antiplatelet signal. The American Heart Association's 2019 primary prevention guideline already cautions against unmonitored supplements with antiplatelet properties in patients on dual antiplatelet therapy [8].

2. Immune priming at the injection site. Alirocumab is given subcutaneously. Reishi beta-glucans activate pattern-recognition receptors (Dectin-1, TLR-2) on skin-resident macrophages [5]. The overlap is plausible but undocumented.

3. Additive LDL reduction. As noted, the magnitude of reishi's lipid effect is clinically negligible compared with alirocumab's potency.

Who Is Most at Risk from This Combination?

Not every patient on Praluent faces the same level of concern. Risk stratification depends on bleeding history, concurrent medications, and immune status.

High-Risk Patients

Patients concurrently taking warfarin (INR target 2.0 to 3.0) or dual antiplatelet therapy (DAPT) after recent percutaneous coronary intervention carry the highest marginal risk from adding reishi. The ODYSSEY OUTCOMES population included 29.4% of patients on DAPT at baseline [1]. Adding an herbal antiplatelet agent to that regimen introduces unpredictable variability.

Patients with autoimmune conditions (rheumatoid arthritis, lupus, inflammatory bowel disease) should also exercise caution. Reishi's Th1-skewing cytokine profile could theoretically exacerbate Th1-driven autoimmune flares [5].

Lower-Risk Patients

A patient taking alirocumab as monotherapy for heterozygous familial hypercholesterolemia, with no anticoagulant or antiplatelet use and no autoimmune history, faces minimal added risk from a standard reishi dose (1 to 1.5 g/day of dried extract). The interaction concern is real but dose-dependent and context-dependent.

Monitoring Plan If You Take Both

If a patient and their prescriber decide to continue both agents, a structured monitoring protocol reduces the chance of missing an adverse signal.

Baseline Labs Before Adding Reishi

Draw a CBC with differential and platelet count, a comprehensive metabolic panel (CMP) including ALT and AST, and a fasting lipid panel. These establish the pre-supplement reference range.

Follow-Up at 8 to 12 Weeks

Repeat the same panel. Key thresholds to flag:

• Platelet count drop of more than 15% from baseline
• ALT or AST rise above 2x the upper limit of normal (reishi hepatotoxicity has been reported in at least three published case reports at doses exceeding 3 g/day) [9]
• Any unexplained bruising, gum bleeding, or prolonged bleeding from minor cuts

Ongoing Surveillance

If the 8-to-12-week panel is clean, repeat monitoring can move to the patient's standard alirocumab follow-up cadence (every 3 to 6 months). Patients should report new bruising, dark stools, or injection-site reactions that are more painful or swollen than prior injections.

What to Do If You Are Already Taking Both

Many patients start reishi on their own before discussing it with their cardiologist. The correct response is disclosure, not panic.

Step 1: Tell Your Prescriber

Bring the exact product (brand, dose, frequency) to your next appointment. "Reishi mushroom" covers hundreds of products with varying ganoderic acid concentrations. The prescriber cannot assess risk without knowing the dose.

Step 2: Review Your Full Medication List

The interaction concern scales with the total number of agents affecting hemostasis. If you take aspirin 81 mg, clopidogrel 75 mg, and reishi 1.5 g daily alongside Praluent, the antiplatelet "stack" is four agents deep. Your prescriber may recommend discontinuing the reishi or, alternatively, dropping one of the pharmaceutical antiplatelets if your ASCVD risk profile permits.

Step 3: Lab Check

Even if you feel fine, a CBC and LFT draw confirms there is no subclinical platelet depression or hepatic injury. Reishi-associated hepatotoxicity is rare but documented. A 2019 case report in the Journal of Hepatology described a 47-year-old woman who developed severe cholestatic hepatitis after 8 weeks of powdered reishi at 4 g/day, with full resolution after discontinuation [9].

Reishi Dose Ranges and Quality Considerations

Supplement quality variability introduces a separate safety variable that pharmaceutical monoclonal antibodies do not share.

Typical Dosing in Published Studies

Clinical trials have used dried Ganoderma lucidum extract at doses ranging from 1.44 g/day to 5.4 g/day for durations of 12 to 16 weeks [6]. The triterpenoid content varies by extraction method. Hot-water extracts are rich in polysaccharides but low in ganoderic acids; ethanol extracts concentrate the triterpenoids responsible for antiplatelet activity [3].

Third-Party Testing Matters

The FDA does not approve dietary supplements for safety or efficacy before they reach shelves. A 2017 analysis by ConsumerLab found that 6 of 12 tested reishi products contained less than 50% of the beta-glucan content stated on the label. Patients should look for products bearing a USP Verified, NSF International, or ConsumerLab seal, which confirms identity, potency, and absence of heavy-metal contamination.

The Bottom Line for Clinicians and Patients

No published evidence demonstrates a dangerous interaction between reishi mushroom and alirocumab. The theoretical risks are pharmacodynamic: additive antiplatelet effects in patients already on antithrombotic therapy, immune modulation at the injection site, and rare hepatotoxicity from reishi itself. These risks are manageable with disclosure, baseline labs, and follow-up monitoring at 8 to 12 weeks. Patients taking DAPT or anticoagulants alongside Praluent should avoid reishi until discussing it with their prescriber. For patients on alirocumab monotherapy without bleeding risk factors, a standard-dose reishi product (1 to 1.5 g/day, third-party tested) represents a low but not zero-risk addition.

The Endocrine Society and the American College of Cardiology have not issued formal guidance on supplement co-administration with PCSK9 inhibitors [10]. Until that changes, shared decision-making between patient and prescriber, supported by lab monitoring, remains the standard of care.